menu
    • menu
    [{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MC4R","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Private Placement","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Vivani Medical","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subdermal Implant","sponsorNew":"Vivani Medical \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Vivani Medical \/ Undisclosed"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GIP\/GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Retatrutide","moa":"GLP1\/GIP\/GCG receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Lexicon pharmaceuticals","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Licensing Agreement","leadProduct":"LX9851","moa":"ACSL5","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexicon pharmaceuticals","amount2":1,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":1,"dosageForm":"Oral","sponsorNew":"Lexicon pharmaceuticals \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lexicon pharmaceuticals \/ Novo Nordisk"},{"orgOrder":0,"company":"Corbus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CRB-913","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Corbus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corbus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Corbus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"PDL BioPharma","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Deoxycholic Acid","moa":"Cell membrane","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PDL BioPharma","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PDL BioPharma \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"PDL BioPharma \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Benuvia","sponsor":"Avernus Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Licensing Agreement","leadProduct":"Tetrahydrocannabinol","moa":"CB1\/CB2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Benuvia","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Solution","sponsorNew":"Benuvia \/ Avernus Pharma","highestDevelopmentStatusID":"15","companyTruncated":"Benuvia \/ Avernus Pharma"},{"orgOrder":0,"company":"Currax","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Naltrexone Hydrochloride","moa":"||Kappa\/Mu\/delta-Opioid receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Currax","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet, Extended Release","sponsorNew":"Currax \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Currax \/ Inapplicable"},{"orgOrder":0,"company":"nuBioAge","sponsor":"Marius Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Collaboration","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"nuBioAge","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"nuBioAge \/ Marius Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"nuBioAge \/ Marius Pharmaceuticals"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Cowen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Public Offering","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Cowen","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Cowen"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Genpharm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Genpharm","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Genpharm"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"HealthCare Royalty Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Agreement","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ HealthCare Royalty Partners"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"RareStone Group","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Termination","leadProduct":"Setmelanotide Acetate","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"RareStone Group","amount2":0.01,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.01,"dosageForm":"Subcutaneous Injection","sponsorNew":"RareStone Group \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"RareStone Group \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Short Wave Pharma","sponsor":"The Sheba Center for Eating Disorders","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2022","type":"Agreement","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Short Wave Pharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Short Wave Pharma \/ The Sheba Center for Eating Disorders","highestDevelopmentStatusID":"7","companyTruncated":"Short Wave Pharma \/ The Sheba Center for Eating Disorders"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Artelo Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Cannabinoid","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Artelo Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Artelo Biosciences \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Artelo Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Helsinn Advanced Synthesis","sponsor":"Oberland Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Anamorelin HCl","moa":"GHS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Helsinn Advanced Synthesis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Helsinn Advanced Synthesis \/ Oberland Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Helsinn Advanced Synthesis \/ Oberland Capital Management"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Radicle Science","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"InMed Pharmaceuticals \/ Radicle Science","highestDevelopmentStatusID":"15","companyTruncated":"InMed Pharmaceuticals \/ Radicle Science"},{"orgOrder":0,"company":"Cronos Group","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"CBR","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cronos Group","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cronos Group \/ Ginkgo Bioworks","highestDevelopmentStatusID":"1","companyTruncated":"Cronos Group \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Anglo-French Drugs and industries","sponsor":"Lupin Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Acquisition","leadProduct":"Nicotinamide","moa":"Fatty-acid amide hydrolase-1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Anglo-French Drugs and industries","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Anglo-French Drugs and industries \/ Lupin Ltd","highestDevelopmentStatusID":"15","companyTruncated":"Anglo-French Drugs and industries \/ Lupin Ltd"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Series B Financing","leadProduct":"Pindolol","moa":"Beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Actimed Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"TCMCB07","moa":"MC3\/MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Ono Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Anamorelin HCl","moa":"GHS receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Ono Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ono Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Ono Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Orbit Discovery","sponsor":"Endevica Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Orbit Discovery","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orbit Discovery \/ Endevica Bio","highestDevelopmentStatusID":"2","companyTruncated":"Orbit Discovery \/ Endevica Bio"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Mankind Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"S-Pindolol Benzoate","moa":"5-HTA1a\/beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Mankind Pharma","highestDevelopmentStatusID":"8","companyTruncated":"Actimed Therapeutics \/ Mankind Pharma"},{"orgOrder":0,"company":"Actimed Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Oxprenolol","moa":"Adrenergic-beta-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Actimed Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Actimed Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Actimed Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Immuneering Corporation","sponsor":"Boxcar Pmj","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"KRAS","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Immuneering Corporation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immuneering Corporation \/ Boxcar Pmj","highestDevelopmentStatusID":"1","companyTruncated":"Immuneering Corporation \/ Boxcar Pmj"},{"orgOrder":0,"company":"VistaGen Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PH284","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"VistaGen Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"VistaGen Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"VistaGen Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Green Cross Well-being","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"BST204","moa":"IL-6 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Green Cross Well-being","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Green Cross Well-being \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Green Cross Well-being \/ Inapplicable"},{"orgOrder":0,"company":"Novo Integrated Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Iodine","moa":"Immunostimulant","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Novo Integrated Sciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Spray","sponsorNew":"Novo Integrated Sciences \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Novo Integrated Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"nACh-alpha-7 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Baymedica","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2021","type":"Acquisition","leadProduct":"Cannabichromene","moa":"TRPA1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baymedica","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Baymedica \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Baymedica \/ InMed Pharmaceuticals"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2022","type":"Inapplicable","leadProduct":"Magnesium","moa":"||Oxytocin receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Aardvark Therapeutics","sponsor":"Morgan Stanley","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"Denatonium Acetate","moa":"TAS2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Aardvark Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.089999999999999997,"dosageForm":"Oral","sponsorNew":"Aardvark Therapeutics \/ Morgan Stanley","highestDevelopmentStatusID":"10","companyTruncated":"Aardvark Therapeutics \/ Morgan Stanley"},{"orgOrder":0,"company":"Oranda Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"IRELAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Oranda Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oranda Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Oranda Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"RM-718","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2021","type":"Inapplicable","leadProduct":"Zinc","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Theratechnologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"Tesamorelin Acetate","moa":"GHRF","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Theratechnologies","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Theratechnologies \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Theratechnologies \/ Inapplicable"},{"orgOrder":0,"company":"Cystic Fibrosis Foundation","sponsor":"Synspira Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Agreement","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Cystic Fibrosis Foundation","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Cystic Fibrosis Foundation \/ Synspira Therapeutics","highestDevelopmentStatusID":"1","companyTruncated":"Cystic Fibrosis Foundation \/ Synspira Therapeutics"},{"orgOrder":0,"company":"Anagram Therapeutics","sponsor":"Cystic Fibrosis Foundation","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Enzyme","year":"2020","type":"Funding","leadProduct":"SNSP003","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Anagram Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Anagram Therapeutics \/ Cystic Fibrosis Foundation","highestDevelopmentStatusID":"4","companyTruncated":"Anagram Therapeutics \/ Cystic Fibrosis Foundation"},{"orgOrder":0,"company":"Abbott Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Elecare","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Abbott Laboratories","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Dry Powder","sponsorNew":"Abbott Laboratories \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Abbott Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Funding","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Elgan Pharma \/ European Innovation Council","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ European Innovation Council"},{"orgOrder":0,"company":"Elgan Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Recombinant Human Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Elgan Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Powder","sponsorNew":"Elgan Pharma \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Elgan Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Baxter Healthcare Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Olive","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Baxter Healthcare Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Baxter Healthcare Corporation \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Baxter Healthcare Corporation \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Potassium Phosphate","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Protara Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Choline Chloride","moa":"nACh-alpha-7 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Protara Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Protara Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Protara Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"ChromaDex, Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Nicotinamide Riboside Chloride","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"ChromaDex, Inc","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"ChromaDex, Inc \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"ChromaDex, Inc \/ Inapplicable"},{"orgOrder":0,"company":"Sinopharm","sponsor":"ChromaDex, Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Agreement","leadProduct":"Nicotinamide Riboside","moa":"NAD","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Sinopharm","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sinopharm \/ ChromaDex, Inc","highestDevelopmentStatusID":"15","companyTruncated":"Sinopharm \/ ChromaDex, Inc"},{"orgOrder":0,"company":"Nestl\u00e9 India Limited","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Biotin","moa":"||Oligodendrocytes myelin synthesis","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nestl\u00e9 India Limited","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Nestl\u00e9 India Limited \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Nestl\u00e9 India Limited \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"9 Meters Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"NM-136","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"9 Meters Biopharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"9 Meters Biopharma \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"9 Meters Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Laekna Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"LAE102","moa":"Activin type-2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Laekna Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Laekna Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"Laekna Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"MSTN activation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"MSTN activation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Apitegromab","moa":"MSTN activation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Acquisition","leadProduct":"Bimagrumab","moa":"||Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Eli Lilly"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Versanis Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"Bimagrumab","moa":"||Activin type-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Versanis Bio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Versanis Bio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Versanis Bio \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Beacon Biosignals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Beacon Biosignals","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Beacon Biosignals"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Beacon Biosignals","sponsor":"Skye Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Collaboration","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Beacon Biosignals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Beacon Biosignals \/ Skye Bioscience","highestDevelopmentStatusID":"6","companyTruncated":"Beacon Biosignals \/ Skye Bioscience"},{"orgOrder":0,"company":"Iconovo","sponsor":"Lonza Group","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWEDEN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"Iconovo","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Iconovo \/ Lonza Group","highestDevelopmentStatusID":"1","companyTruncated":"Iconovo \/ Lonza Group"},{"orgOrder":0,"company":"Deep Apple Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Deep Apple Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Deep Apple Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"2","companyTruncated":"Deep Apple Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Ascenta Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series B Financing","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Ascenta Capital","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Ascenta Capital"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TLC-6740","moa":"AMPK","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"OrsoBio \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"TERN-601","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Terns Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ventyx Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ventyx Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ventyx Biosciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Ventyx Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Evotec","sponsor":"Inserm","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evotec \/ Inserm","highestDevelopmentStatusID":"2","companyTruncated":"Evotec \/ Inserm"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Driehaus Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"BELGIUM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Confo Therapeutics \/ Driehaus Capital Management","highestDevelopmentStatusID":"2","companyTruncated":"Confo Therapeutics \/ Driehaus Capital Management"},{"orgOrder":0,"company":"NIMIUM Therapeutics","sponsor":"Paraza Pharma","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"NIMIUM Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"NIMIUM Therapeutics \/ Paraza Pharma","highestDevelopmentStatusID":"4","companyTruncated":"NIMIUM Therapeutics \/ Paraza Pharma"},{"orgOrder":0,"company":"MindRank","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MDR-001","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"MindRank \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"MindRank \/ Inapplicable"},{"orgOrder":0,"company":"Embark Biotech","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Embark Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Embark Biotech \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Embark Biotech \/ Novo Nordisk"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"VENT-01","moa":"NLRP3","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Ascendis Pharma","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Ascendis Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ascendis Pharma \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Ascendis Pharma \/ Novo Nordisk"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Semaglutide","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"PeptiDream \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"PeptiDream \/ Inapplicable"},{"orgOrder":0,"company":"LG Chem","sponsor":"Rhythm Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"LG Chem","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"LG Chem \/ Rhythm Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"LG Chem \/ Rhythm Pharmaceuticals"},{"orgOrder":0,"company":"Dx&Vx","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Dx&Vx","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dx&Vx \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dx&Vx \/ Inapplicable"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"Eracal Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Eracal Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eracal Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Eracal Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"HAYA Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"HAYA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"HAYA Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"HAYA Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Aphaia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Dextrose","moa":"Blood glucose level","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Aphaia Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Aphaia Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Aphaia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Verdiva Bio","sponsor":"Forbion","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2025","type":"Series A Financing","leadProduct":"VRB-101","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Verdiva Bio","amount2":0.40999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.40999999999999998,"dosageForm":"Oral","sponsorNew":"Verdiva Bio \/ Forbion","highestDevelopmentStatusID":"6","companyTruncated":"Verdiva Bio \/ Forbion"},{"orgOrder":0,"company":"VedTechBio","sponsor":"RenaissThera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"VedTechBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"VedTechBio \/ RenaissThera","highestDevelopmentStatusID":"3","companyTruncated":"VedTechBio \/ RenaissThera"},{"orgOrder":0,"company":"Korro Bio","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Korro Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Korro Bio \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Korro Bio \/ Novo Nordisk"},{"orgOrder":0,"company":"Metaphore Biotechnologies","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Metaphore Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Metaphore Biotechnologies \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Metaphore Biotechnologies \/ Novo Nordisk"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Omega Therapeutics \/ Novo Nordisk","highestDevelopmentStatusID":"3","companyTruncated":"Omega Therapeutics \/ Novo Nordisk"},{"orgOrder":0,"company":"ProFound Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"ProFound Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"ProFound Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"ProFound Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Kintai Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"KTX-0200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Kintai Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kintai Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Kintai Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RGT-075","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Regor Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"RGT-075","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Regor Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regor Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Regor Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Bivamelagon","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Rhythm Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Rhythm Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Intarcia","sponsor":"i2o Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"i2o-105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Intarcia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Intarcia \/ i2o Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Intarcia \/ i2o Therapeutics"},{"orgOrder":0,"company":"Senda Biosciences","sponsor":"Nestle Health Sciences SA","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Senda Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Senda Biosciences \/ Nestle Health Sciences SA","highestDevelopmentStatusID":"4","companyTruncated":"Senda Biosciences \/ Nestle Health Sciences SA"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"A07D","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Endevica Bio \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Endevica Bio \/ Inapplicable"},{"orgOrder":0,"company":"Kallyope","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kallyope \/ Novo Nordisk","highestDevelopmentStatusID":"2","companyTruncated":"Kallyope \/ Novo Nordisk"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Regeneron Pharmaceuticals \/ AstraZeneca","highestDevelopmentStatusID":"2","companyTruncated":"Regeneron Pharmaceuticals \/ AstraZeneca"},{"orgOrder":0,"company":"Ampersand Biosciences","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Ampersand Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Ampersand Biosciences \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Ampersand Biosciences \/ Flagship Pioneering"},{"orgOrder":0,"company":"Kallyope","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"K-757","moa":"||Nutrient receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Kallyope","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Kallyope \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Kallyope \/ Inapplicable"},{"orgOrder":0,"company":"Biorestorative Therapies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biorestorative Therapies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biorestorative Therapies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biorestorative Therapies \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX-7006","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Metabolexis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"MLX7000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biolexis Therapeutics \/ Metabolexis","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Metabolexis"},{"orgOrder":0,"company":"Virginia Tech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"BAM 15","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Virginia Tech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Virginia Tech \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Virginia Tech \/ Inapplicable"},{"orgOrder":0,"company":"Lumen Bioscience","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lumen Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Lumen Bioscience \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Lumen Bioscience \/ Novo Nordisk"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2025","type":"Inapplicable","leadProduct":"PG-102","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Inapplicable"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Eli Lilly","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Eli Lilly"},{"orgOrder":0,"company":"BioAge Labs","sponsor":"Sofinnova Investments","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Series D Financing","leadProduct":"Azelaprag","moa":"||Apelin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"BioAge Labs","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"BioAge Labs \/ Sofinnova Investments","highestDevelopmentStatusID":"8","companyTruncated":"BioAge Labs \/ Sofinnova Investments"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"ProGen","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Partnership","leadProduct":"RT-114","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Rani Therapeutics \/ ProGen","highestDevelopmentStatusID":"6","companyTruncated":"Rani Therapeutics \/ ProGen"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Raymond James & Associates, Inc.","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Public Offering","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Raymond James & Associates, Inc.","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Raymond James & Associates, Inc."},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Aegis Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Public Offering","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Aegis Capital","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Aegis Capital"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Hebrew University of Jerusalem","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Agreement","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Hebrew University of Jerusalem","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Hebrew University of Jerusalem"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"||5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Clearmind Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"5-Methoxy-2-Aminoindane","moa":"5-HT1A receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Clearmind Medicine","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Clearmind Medicine \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Clearmind Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Lexaria Bioscience","sponsor":"Can-Fite BioPharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Lexaria Bioscience","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lexaria Bioscience \/ Can-Fite BioPharma","highestDevelopmentStatusID":"4","companyTruncated":"Lexaria Bioscience \/ Can-Fite BioPharma"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"XW014","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"TargEDys","sponsor":"Inoliva","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Hafnia alvei HA4597","moa":"Alpha-MSH","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"TargEDys","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TargEDys \/ Inoliva","highestDevelopmentStatusID":"15","companyTruncated":"TargEDys \/ Inoliva"},{"orgOrder":0,"company":"Biophytis","sponsor":"ATLAS PHARMS LLC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ ATLAS PHARMS LLC","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ ATLAS PHARMS LLC"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"20-Hydroxyecdysone","moa":"MAS receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Biophytis \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Biophytis \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Chugai Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Orforglipron Calcium Hydrate","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Eli Lilly \/ Chugai Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Chugai Pharmaceutical"},{"orgOrder":0,"company":"Gelesis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citric Acid","moa":"||NGLY1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Gelesis","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Gelesis \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Gelesis \/ Inapplicable"},{"orgOrder":0,"company":"PureTech Health","sponsor":"Gelesis","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Citric Acid","moa":"||NGLY1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PureTech Health","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"PureTech Health \/ Gelesis","highestDevelopmentStatusID":"15","companyTruncated":"PureTech Health \/ Gelesis"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"IDG Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Series C Financing","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ IDG Capital","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ IDG Capital"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Ecnoglutide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sciwind Biosciences \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sanofi","sponsor":"Sciwind Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Peptide","year":"2021","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sanofi","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Sanofi \/ Sciwind Biosciences","highestDevelopmentStatusID":"4","companyTruncated":"Sanofi \/ Sciwind Biosciences"},{"orgOrder":0,"company":"Metsera","sponsor":"Arch Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Injection","sponsorNew":"Metsera \/ Arch Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ Arch Ventures"},{"orgOrder":0,"company":"Rani Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Rani Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"Rani Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Rani Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2023","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"||CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"4","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ERX-1000","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Pill","sponsorNew":"RespireRx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"RespireRx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Scilex Pharmaceuticals","sponsor":"IPMC","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Scilex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Scilex Pharmaceuticals \/ IPMC","highestDevelopmentStatusID":"8","companyTruncated":"Scilex Pharmaceuticals \/ IPMC"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Viking Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Viking Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"OPKO Health","sponsor":"EnteraBio Ltd","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"OPKO Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"OPKO Health \/ EnteraBio Ltd","highestDevelopmentStatusID":"4","companyTruncated":"OPKO Health \/ EnteraBio Ltd"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"ASC41","moa":"TH-beta-receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Verdiva Bio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"Ecnoglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Sciwind Biosciences","amount2":2.4700000000000002,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.4700000000000002,"dosageForm":"Oral Tablet","sponsorNew":"Sciwind Biosciences \/ Verdiva Bio","highestDevelopmentStatusID":"8","companyTruncated":"Sciwind Biosciences \/ Verdiva Bio"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Eccogene","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"8","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Vincentage Pharma","sponsor":"Corxel Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Acquisition","leadProduct":"VCT220","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Vincentage Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Vincentage Pharma \/ Corxel Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Vincentage Pharma \/ Corxel Pharmaceuticals"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Amycretin","moa":"GLP-1\/Amylin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"Saniona","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Tesofensine","moa":"||Triple monoamine reuptake","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Saniona","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Saniona \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Saniona \/ Inapplicable"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Biologics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Teduglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"EnteraBio Ltd \/ OPKO Biologics","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Biologics"},{"orgOrder":0,"company":"Neurobiogen","sponsor":"Scilex Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Tisolagiline","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Neurobiogen","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Neurobiogen \/ Scilex Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Neurobiogen \/ Scilex Pharmaceuticals"},{"orgOrder":0,"company":"PLT Health Solutions","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Curcumin","moa":"||Immuno","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"PLT Health Solutions","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"PLT Health Solutions \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"PLT Health Solutions \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Danuglipron","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Danuglipron","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Pfizer Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Pfizer Inc \/ Inapplicable"},{"orgOrder":0,"company":"CordenPharma","sponsor":"Viking Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2025","type":"Partnership","leadProduct":"VK2735","moa":"GLP-1\/GIP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"CordenPharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"CordenPharma \/ Viking Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"CordenPharma \/ Viking Therapeutics"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Rivus Pharmaceuticals","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Series B Financing","leadProduct":"HU6","moa":"Sugar oxidation","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Rivus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Rivus Pharmaceuticals \/ RA Capital Management","highestDevelopmentStatusID":"8","companyTruncated":"Rivus Pharmaceuticals \/ RA Capital Management"},{"orgOrder":0,"company":"Adocia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"FRANCE","productType":"Other Large Molecule","year":"2021","type":"Inapplicable","leadProduct":"Pramlintide","moa":"||AMY1\/CALCR\/RAMP1","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Adocia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Infusion","sponsorNew":"Adocia \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Adocia \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide-antibody Conjugate","year":"2022","type":"Inapplicable","leadProduct":"AMG 133","moa":"GIPR \/GLP-1","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"AMG 513","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Helicore Biopharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"HCR-188","moa":"GIP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Helicore Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Helicore Biopharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Helicore Biopharma \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-INHBE","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ASC47","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Antibody","year":"2021","type":"Inapplicable","leadProduct":"GMA106","moa":"GIPR","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gmax Biopharm \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Biopharm \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"DR10624","moa":"GLP-1\/GCG\/FGF21 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zhejiang Doer Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2020","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Gan & Lee Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bofanglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Gan & Lee Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gan & Lee Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Gan & Lee Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Eli Lilly","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Eli Lilly"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Innovent Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Mazdutide","moa":"GLP-1\/GCGR receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Innovent Biologics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Innovent Biologics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Innovent Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Jiangsu Hengrui Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Jiangsu Hengrui Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Jiangsu Hengrui Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Jiangsu Hengrui Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Collaboration","leadProduct":"CT-388","moa":"||GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":5.2999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":5.2999999999999998,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Gubra","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":2.23,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.23,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ AbbVie Inc","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ AbbVie Inc"},{"orgOrder":0,"company":"Gubra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Gubra \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Fleroxacin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Goldman Sachs International","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Goldman Sachs International","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Goldman Sachs International"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Dapiglutide","moa":"GLP-1\/GLP-2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Carnegie Investment Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Carnegie Investment Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Carnegie Investment Bank"},{"orgOrder":0,"company":"The United Laboratories","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"HONG KONG","productType":"Peptide","year":"2025","type":"Licensing Agreement","leadProduct":"UBT251","moa":"GLP-1\/GIP\/Glucagon receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"The United Laboratories","amount2":2,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2,"dosageForm":"Subcutaneous Injection","sponsorNew":"The United Laboratories \/ Novo Nordisk","highestDevelopmentStatusID":"8","companyTruncated":"The United Laboratories \/ Novo Nordisk"},{"orgOrder":0,"company":"Merdury Pharmaceutical","sponsor":"Health2Sync","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Merdury Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Merdury Pharmaceutical \/ Health2Sync","highestDevelopmentStatusID":"4","companyTruncated":"Merdury Pharmaceutical \/ Health2Sync"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Kailera Therapeutics","sponsor":"Atlas Venture","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"HRS9531","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Kailera Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Kailera Therapeutics \/ Atlas Venture","highestDevelopmentStatusID":"10","companyTruncated":"Kailera Therapeutics \/ Atlas Venture"},{"orgOrder":0,"company":"AstralBio","sponsor":"iBio","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Licensing Agreement","leadProduct":"IBIO-600","moa":"MSTN","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"AstralBio","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.029999999999999999,"dosageForm":"Subcutaneous Injection","sponsorNew":"AstralBio \/ iBio","highestDevelopmentStatusID":"4","companyTruncated":"AstralBio \/ iBio"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Metsera","sponsor":"Altasciences Company Inc","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ Altasciences Company Inc","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Altasciences Company Inc"},{"orgOrder":0,"company":"Metsera","sponsor":"Wellington Management","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Series B Financing","leadProduct":"MET-097i","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ Wellington Management","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Wellington Management"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.28000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"BofA Securities","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Public Offering","leadProduct":"MET097","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0.32000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.32000000000000001,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ BofA Securities","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ BofA Securities"},{"orgOrder":0,"company":"Metsera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"MET-097i","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Metsera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Metsera \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Metsera \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CIN-110","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CinRx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"CIN-110","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"CinRx Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Inapplicable"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2021","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Zealand Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Survodutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Boehringer Ingelheim GmbH \/ Zealand Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Boehringer Ingelheim GmbH \/ Zealand Pharma"},{"orgOrder":0,"company":"Daewoong Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Daewoong Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Microneedle Patch","sponsorNew":"Daewoong Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Daewoong Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Transdermal Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Transdermal Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Transdermal Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Vivani Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Exenatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vivani Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Transdermal Implant","sponsorNew":"Vivani Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Vivani Medical \/ Inapplicable"},{"orgOrder":0,"company":"Genentech","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Genentech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CT-996","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Genentech","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genentech \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Genentech \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"ARO-ALK7","moa":"ACVR1C","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Arrowhead Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrowhead Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Arrowhead Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"GSBR-1290","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I\/ Phase II","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Maridebart Cafraglutide","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amgen Inc \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Amgen Inc \/ Inapplicable"},{"orgOrder":0,"company":"Lipidio Pharmaceuticals","sponsor":"Maxim Merchant Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Series A Financing","leadProduct":"GDD3898","moa":"SCD1","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipidio Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital","highestDevelopmentStatusID":"8","companyTruncated":"Lipidio Pharmaceuticals \/ Maxim Merchant Capital"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Insulin","moa":"Insulin receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modular Medical \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Modular Medical \/ Inapplicable"},{"orgOrder":0,"company":"Structure Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ACCG-2671","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Structure Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Structure Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Structure Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"ZyVersa Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Private Placement","leadProduct":"IC 100-08","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"ZyVersa Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ZyVersa Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"ZyVersa Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"Sable Therapeutics","sponsor":"Columbia University","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"SBL-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Sable Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sable Therapeutics \/ Columbia University","highestDevelopmentStatusID":"4","companyTruncated":"Sable Therapeutics \/ Columbia University"},{"orgOrder":0,"company":"InMed Pharmaceuticals","sponsor":"Baymedica","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CANADA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tetrahydrocannabivarin","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"InMed Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InMed Pharmaceuticals \/ Baymedica","highestDevelopmentStatusID":"1","companyTruncated":"InMed Pharmaceuticals \/ Baymedica"},{"orgOrder":0,"company":"TransThera Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TT-02332","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"TransThera Biosciences","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TransThera Biosciences \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"TransThera Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Hansoh Pharma","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"HS-10535","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Hansoh Pharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hansoh Pharma \/ Merck & Co","highestDevelopmentStatusID":"4","companyTruncated":"Hansoh Pharma \/ Merck & Co"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antag Therapeutic \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Antag Therapeutic \/ Inapplicable"},{"orgOrder":0,"company":"Antag Therapeutic","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Series A Financing","leadProduct":"AT-7687","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Antag Therapeutic","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antag Therapeutic \/ Versant Ventures","highestDevelopmentStatusID":"5","companyTruncated":"Antag Therapeutic \/ Versant Ventures"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Cytoki Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"CK-0045","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Cytoki Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoki Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Cytoki Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BI 1820237","moa":"||Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Monlunabant","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Skandinaviska Enskilda Banken","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2023","type":"Public Offering","leadProduct":"Amylin","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gubra \/ Skandinaviska Enskilda Banken","highestDevelopmentStatusID":"4","companyTruncated":"Gubra \/ Skandinaviska Enskilda Banken"},{"orgOrder":0,"company":"Tetra Pharm Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"TPT0701","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tetra Pharm Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tetra Pharm Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tetra Pharm Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Can-Fite BioPharma","sponsor":"Univo Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Controlled Substance","year":"2020","type":"Inapplicable","leadProduct":"Cannabidiol","moa":"CB1\/2 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Can-Fite BioPharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Can-Fite BioPharma \/ Univo Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Can-Fite BioPharma \/ Univo Pharmaceuticals"},{"orgOrder":0,"company":"EnteraBio Ltd","sponsor":"OPKO Health","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Oxyntomodulin Analog","moa":"GCGR\/GLP-1R","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"EnteraBio Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EnteraBio Ltd \/ OPKO Health","highestDevelopmentStatusID":"4","companyTruncated":"EnteraBio Ltd \/ OPKO Health"},{"orgOrder":0,"company":"SciSparc","sponsor":"Clearmind Medicine","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2022","type":"Collaboration","leadProduct":"Palmitoylethanolamide","moa":"||TNF-alpha receptor","graph1":"Nutrition and Weight Loss","graph2":"Undisclosed","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ Clearmind Medicine","highestDevelopmentStatusID":"1","companyTruncated":"SciSparc \/ Clearmind Medicine"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Sanofi","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Sunstone Life Science Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Series A Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Sunstone Life Science Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Sunstone Life Science Ventures"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Resalis Therapeutics","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"ITALY","productType":"Other Large Molecule","year":"2023","type":"Financing","leadProduct":"RES-010","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Resalis Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Resalis Therapeutics \/ Claris Ventures","highestDevelopmentStatusID":"6","companyTruncated":"Resalis Therapeutics \/ Claris Ventures"},{"orgOrder":0,"company":"Yunovia","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"ID110521156","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Yunovia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Yunovia \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Yunovia \/ Inapplicable"},{"orgOrder":0,"company":"KeyBioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Other Large Molecule","year":"2024","type":"Expanded Collaboration","leadProduct":"LY3541105","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"KeyBioscience","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KeyBioscience \/ Eli Lilly","highestDevelopmentStatusID":"6","companyTruncated":"KeyBioscience \/ Eli Lilly"},{"orgOrder":0,"company":"Radella Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"MD-18","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Radella Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Radella Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Radella Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Tiziana Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Foralumab","moa":"||CD3","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Tiziana Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tiziana Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Tiziana Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Glyscend Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"GLY-200","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Glyscend Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glyscend Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Glyscend Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Ampersand Biomedicines","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Discovery Platform","graph3":"Ampersand Biomedicines","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Ampersand Biomedicines \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Ampersand Biomedicines \/ Flagship Pioneering"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"KER-065","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Keros Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Wave Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"WVE-007","moa":"INHBE","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Wave Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Wave Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Wave Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Xeno Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"XEN-101","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Xeno Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Xeno Biosciences \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Xeno Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Fractyl Health","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"RJVA-001","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Fractyl Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fractyl Health \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Fractyl Health \/ Inapplicable"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"HCAb","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Harbour BioMed \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"SRK-439","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Large Molecule","year":"2023","type":"Inapplicable","leadProduct":"SRK-439","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scholar Rock \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Scholar Rock \/ Inapplicable"},{"orgOrder":0,"company":"Valo Health","sponsor":"Novo Nordisk","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Valo Health","amount2":4.79,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":4.79,"dosageForm":"Undisclosed","sponsorNew":"Valo Health \/ Novo Nordisk","highestDevelopmentStatusID":"4","companyTruncated":"Valo Health \/ Novo Nordisk"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Metsera","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"MET-097","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amneal Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amneal Pharmaceuticals \/ Metsera","highestDevelopmentStatusID":"6","companyTruncated":"Amneal Pharmaceuticals \/ Metsera"},{"orgOrder":0,"company":"Relmada Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Controlled Substance","year":"2024","type":"Inapplicable","leadProduct":"Psilocybine","moa":"5-HT2A receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Relmada Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Relmada Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Relmada Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Ireland","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Janssen Ireland","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Janssen Ireland"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"GDF-15","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"},{"orgOrder":0,"company":"KVK.Tech","sponsor":"Medix","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Phentermine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"KVK.Tech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"KVK.Tech \/ Medix","highestDevelopmentStatusID":"15","companyTruncated":"KVK.Tech \/ Medix"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Gubra","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"GERMANY","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"BI 3034701","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Gubra","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Gubra"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"BLX 0871","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"IND Enabling","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Biolexis Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Biolexis Therapeutics","sponsor":"Clarke Capital","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Series A Financing","leadProduct":"MLX0800","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Biolexis Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biolexis Therapeutics \/ Clarke Capital","highestDevelopmentStatusID":"4","companyTruncated":"Biolexis Therapeutics \/ Clarke Capital"},{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"CHINA","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"ASC30","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Ascletis Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Skye Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Antibody","year":"2024","type":"Inapplicable","leadProduct":"Nimacimab","moa":"CB1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Skye Bioscience","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Skye Bioscience \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Skye Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Bremelanotide Acetate","moa":"||MCR","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Altimmune","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Pemvidutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Altimmune","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Altimmune \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Altimmune \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2025","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Cagrilintide","moa":"||Amylin\/calcitonin receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Novo Nordisk \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Novo Nordisk \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2025","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Bio-Path Holdings","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2024","type":"Inapplicable","leadProduct":"Prexigebersen","moa":"GRB2","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Bio-Path Holdings","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Bio-Path Holdings \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Bio-Path Holdings \/ Inapplicable"},{"orgOrder":0,"company":"Tonix Pharmaceuticals Holding Corp","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2023","type":"Inapplicable","leadProduct":"Oxytocin","moa":"CGRP receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Tonix Pharmaceuticals Holding Corp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal Spray","sponsorNew":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Tonix Pharmaceuticals Holding Corp \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"PL7737","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral","sponsorNew":"Palatin Technologies \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Palatin Technologies \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"Petrelintide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Zealand Pharma \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Zealand Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Modular Medical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2024","type":"Inapplicable","leadProduct":"GUB014295","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Modular Medical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modular Medical \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Modular Medical \/ Inapplicable"},{"orgOrder":0,"company":"Bloom Science","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Probiotic","year":"2025","type":"Inapplicable","leadProduct":"BL-001","moa":"GABA receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Bloom Science","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Bloom Science \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Bloom Science \/ Inapplicable"},{"orgOrder":0,"company":"Eton Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"L-Cysteine Hydrochloride","moa":"Glutamate-cysteine ligase","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Eton Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Eton Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Eton Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Nexus Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2023","type":"Inapplicable","leadProduct":"Potassium Chloride","moa":"SLC12A1","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Nexus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Nexus Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Nexus Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"Immunis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"IMM01-STEM","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Immunis","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Immunis \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Immunis \/ Inapplicable"},{"orgOrder":0,"company":"Veru","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Enobosarm","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Veru \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Veru \/ Inapplicable"},{"orgOrder":0,"company":"TNF Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Isomyosamine","moa":"TNF-alpha receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"TNF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"TNF Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"TNF Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"American Regent","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Selenious Acid","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"American Regent \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"American Regent \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Caliway Biopharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"TAIWAN","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"CBL-514","moa":"DYRK1b","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Caliway Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Caliway Biopharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Caliway Biopharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"10xbio","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polidocanol","moa":"Endothelial cell","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"10xbio","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"10xbio \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"10xbio \/ Inapplicable"},{"orgOrder":0,"company":"Raziel Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"RZL-012","moa":"Lipolysis","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Raziel Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Raziel Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Raziel Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Oligonucleotide","year":"2022","type":"Inapplicable","leadProduct":"Cotsiranib","moa":"TGF-beta-1\/COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Sirnaomics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Thiamine Hydrochloride","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Cure Pharmaceutical","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Vitamin D3","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Cure Pharmaceutical","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cure Pharmaceutical \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Cure Pharmaceutical \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2025","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"GLAND PHARMA LIMITED","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Inapplicable","leadProduct":"Vitamin K1","moa":"Vitamin K","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"GLAND PHARMA LIMITED","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"GLAND PHARMA LIMITED \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"GLAND PHARMA LIMITED \/ Inapplicable"},{"orgOrder":0,"company":"Altamira Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"BERMUDA","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Betahistine Dihydrochloride","moa":"H1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Altamira Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Nasal","sponsorNew":"Altamira Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Altamira Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Corcept Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Miricorilant","moa":"Glucocorticoid receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Corcept Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Corcept Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Corcept Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"RDX-002","moa":"MTP","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Response Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Epitomee","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"Epitomee","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Epitomee","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Epitomee \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Epitomee \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Eli Lilly","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Peptide","year":"2022","type":"Inapplicable","leadProduct":"Tirzepatide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Eli Lilly","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Eli Lilly \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Eli Lilly \/ Inapplicable"},{"orgOrder":0,"company":"Medix","sponsor":"Biocon","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"MEXICO","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Liraglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Medix","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Medix \/ Biocon","highestDevelopmentStatusID":"15","companyTruncated":"Medix \/ Biocon"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Peptide","year":"2023","type":"Inapplicable","leadProduct":"Semaglutide","moa":"GLP-1 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Dr. Reddy\\'s Laboratories","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Dr. Reddy\\'s Laboratories \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Dr. Reddy\\'s Laboratories \/ Inapplicable"},{"orgOrder":0,"company":"Kindred Biosciences","sponsor":"Dechra Pharmaceuticals Manufacturing","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Divestment","leadProduct":"Mirtazapine","moa":"5-HT2C receptor","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Kindred Biosciences","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Topical","sponsorNew":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing","highestDevelopmentStatusID":"15","companyTruncated":"Kindred Biosciences \/ Dechra Pharmaceuticals Manufacturing"},{"orgOrder":0,"company":"Veos Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"SPAIN","productType":"Hormone","year":"2025","type":"Inapplicable","leadProduct":"ThymoTropin","moa":"MSTN","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Veos Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Veos Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Veos Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SixPeaks Bio \/ AstraZeneca","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks Bio \/ AstraZeneca"},{"orgOrder":0,"company":"SixPeaks Bio","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"SWITZERLAND","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"SixPeaks Bio","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SixPeaks Bio \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"SixPeaks Bio \/ Versant Ventures"},{"orgOrder":0,"company":"National Institute on Aging","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Sulfiram","moa":"Aldehyde dehydrogenase","graph1":"Nutrition and Weight Loss","graph2":"Preclinical","graph3":"National Institute on Aging","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"National Institute on Aging \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"National Institute on Aging \/ Inapplicable"},{"orgOrder":0,"company":"Lipocine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Hormone","year":"2024","type":"Inapplicable","leadProduct":"Testosterone Undecanoate","moa":"||Androgen receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase II","graph3":"Lipocine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Lipocine \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Lipocine \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Mayo Clinic","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Phentermine","moa":"||NET","graph1":"Nutrition and Weight Loss","graph2":"Phase IV","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Mayo Clinic","highestDevelopmentStatusID":"11","companyTruncated":"Vivus \/ Mayo Clinic"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Phentermine","moa":"||NET","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||NET","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral Capsule, Extended Release","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Vivus","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Phentermine","moa":"||NET","graph1":"Nutrition and Weight Loss","graph2":"Approved FDF","graph3":"Vivus","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vivus \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Vivus \/ Inapplicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Danske Bank","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"DENMARK","productType":"Hormone","year":"2023","type":"Private Placement","leadProduct":"Dasiglucagon","moa":"GCGR","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Zealand Pharma \/ Danske Bank","highestDevelopmentStatusID":"10","companyTruncated":"Zealand Pharma \/ Danske Bank"}]

    Find Clinical Drug Pipelines for Nutrition and Weight Loss

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Dr. Reddy's Laboratories

                            India
                            MAGHREB PHARMA
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy’s Labs Gets Nod to Study Popular Weight Loss Medication

                            Details : Semaglutide is a GLP-1 receptor agonist, which is being investigated in Phase 3 for the treatment of weight loss type 2 diabetes and chronic kidney disease.

                            Product Name : Semaglutide-Generic

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 19, 2023

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Dr. Reddy's Laboratories

                            India
                            MAGHREB PHARMA
                            Attending
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Dr Reddy's Gears up for Weight Loss Drug Study

                            Details : subcutaneous semaglutide is a GLP-1 receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults.

                            Product Name : Semaglutide-Generic

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            October 18, 2023

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            Dr Reddy Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sanofi

                            France
                            BIO International Convention
                            Exhibiting
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual BoothSanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.

                            Lead Product(s) : Ecnoglutide,Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Sciwind Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agoni...

                            Details : In the terms of the agreement, Sanofi granted exclusive worldwide rights to Sciwind to develop, manufacture and commercialize Sanofi's GIP receptor agonists including XW003, for all applicable indications.

                            Product Name : XW003

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            November 30, 2021

                            Lead Product(s) : Ecnoglutide,Undisclosed

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Sciwind Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            Sanofi Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Rhythm Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Rhythm Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Setmelanotide Acetate

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Rhythm to Share Phase 3 Results of Setmelanotide for Obesity

                            Details : Imcivree (setmelanotide) is a subcutaneously administered, MC4 R agonist. It is being investigated for the treatment of acquired hypothalamic obesity.

                            Product Name : Imcivree

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            April 01, 2025

                            Lead Product(s) : Setmelanotide Acetate

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Ascletis Pharma

                            China arrow
                            German Wound Congress
                            Not Confirmed

                            Ascletis Pharma

                            China arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ASC30

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30

                            Details : ASC30 is an investigational small-molecule agonist biased toward GLP-1R. It is being evaluated as a once-daily oral tablet for the treatment of obesity.

                            Product Name : ASC30

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 31, 2025

                            Lead Product(s) : ASC30

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Palatin Technologies

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Palatin Technologies

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Palatin's MC4R Agonist Bremelanotide with GLP-1/GIP Tirzepatide Hits Ph 2 Goal

                            Details : Vyleesi (bremelanotide) is a melanocortin receptor 4 agonist (MCR4), which is being evaluated in combination with tirzepatide for obesity.

                            Product Name : Vyleesi

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 31, 2025

                            Lead Product(s) : Bremelanotide Acetate,Tirzepatide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Lexicon pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : LX9851

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Novo Nordisk

                            Deal Size : $1,000.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Lexicon Pharmaceuticals Announces Exclusive License Agreement with Novo Nordisk for LX9851

                            Details : Under the licensing agreement, Novo will hold the rights of LX9851. It is an orally delivered small molecule drug candidate for the treatment of obesity and associated cardiometabolic disorders.

                            Product Name : LX9851

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 28, 2025

                            Lead Product(s) : LX9851

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Novo Nordisk

                            Deal Size : $1,000.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Corbus Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Corbus Pharmaceuticals

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CRB-913

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Corbus Doses First Patient In Phase 1 Trial Of CB1 Agonist CRB-913 for Obesity

                            Details : CRB-913 is a second-generation, highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist drug designed to treat obesity.

                            Product Name : CRB-913

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 28, 2025

                            Lead Product(s) : CRB-913

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Vivani Medical

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Vivani Medical

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $8.2 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Vivani Medical Announces $8.25M Private Placement Equity Financing

                            Details : The net proceeds from the private placement will used to support the clinical development of NPM-139 (semaglutide), which is being evaluated for the treatment of obesity.

                            Product Name : NPM-139

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            March 27, 2025

                            Lead Product(s) : Semaglutide

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Preclinical

                            Sponsor : Undisclosed

                            Deal Size : $8.2 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Viking Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed

                            Viking Therapeutics

                            U.S.A arrow
                            German Wound Congress
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VK2735

                            Therapeutic Area : Nutrition and Weight Loss

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Viking Therapeutics Completes Phase 2 Enrollment for VK2735 Tablet in Obesity

                            Details : Viking investigational product VK2735, which is a Dual GLP-1/GIP Receptor Agonist. Currently, it is being evaluated in the phase I clinical trial studies for the treatment related to obesity.

                            Product Name : VK2735

                            Product Type : Peptide

                            Upfront Cash : Inapplicable

                            March 26, 2025

                            Lead Product(s) : VK2735

                            Therapeutic Area : Nutrition and Weight Loss

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth